Management of Pregnancy with Anti-Fy^a (Duffy) Antibodies
Pregnant women with anti-Fy^a antibodies should be managed using the same surveillance protocols as other clinically significant red cell antibodies (anti-D, anti-c, anti-Kell), including cell-free fetal DNA testing for fetal antigen status, serial middle cerebral artery Doppler monitoring starting at 16 weeks if the fetus is antigen-positive, and planned delivery between 37+0 to 38+6 weeks' gestation if no intrauterine transfusions are required. 1
Initial Assessment and Risk Stratification
Early Pregnancy Evaluation
Obtain cell-free fetal DNA (cffDNA) testing as early as 10 weeks' gestation to determine if the fetus carries the Fy^a antigen 1. This non-invasive test identifies which pregnancies are actually at risk, avoiding unnecessary surveillance in Fy(a)-negative fetuses.
If cffDNA is unavailable, perform paternal genotyping to assess whether the father is homozygous or heterozygous for Fy^a. If homozygous, all pregnancies will be at risk 2.
Document maternal antibody titers at initial presentation. While anti-Fy^a can cause significant hemolytic disease of the fetus and newborn (HDFN), it is less common and typically milder than anti-D 2, 3.
Critical Threshold for Surveillance
Begin intensive fetal surveillance when anti-Fy^a titers reach ≥32, as this threshold identified all cases of significant hemolytic disease in published series 3. Some experts recommend even closer monitoring at titers >64, particularly if the antibody demonstrates functional activity 4.
Fetal Surveillance Protocol
MCA-PSV Doppler Monitoring
Initiate middle cerebral artery peak systolic velocity (MCA-PSV) Doppler at 16 weeks' gestation once fetal Fy^a-positive status is confirmed 1.
Perform MCA-PSV measurements every 1-2 weeks, recognizing that reliability decreases after 35 weeks due to higher false-positive rates 1.
MCA-PSV values >1.5 multiples of the median indicate moderate-to-severe fetal anemia requiring further evaluation 1.
High-Risk Features Requiring Specialized Management
Refer immediately to a tertiary fetal medicine center if:
- Previous pregnancy with fetal anemia or fetal loss due to HDFN before 24 weeks 1
- Rising antibody titers despite surveillance
- Elevated MCA-PSV suggesting fetal anemia
- Any signs of fetal hydrops on ultrasound
Treatment Considerations
Intravenous Immunoglobulin (IVIG)
Consider IVIG therapy (1 g/kg weekly) starting at the end of the first trimester for women with:
- Documented antigen-positive fetus AND
- History of fetal anemia or fetal loss due to HDFN before 24 weeks in a previous pregnancy 1, 2
IVIG represents a non-invasive approach to prevent or delay severe fetal anemia, though evidence quality remains limited 2.
Intrauterine Transfusion (IUT)
If fetal anemia develops (confirmed by cordocentesis showing hemoglobin <40 g/L at 18 weeks or <80 g/L at term):
- Continue IUTs until 35+0 to 35+6 weeks' gestation to minimize neonatal complications 1
- Procedure-related loss rates are 0.9% after 20 weeks but increase to 8.5% before 20 weeks 2
- Survival exceeds 90% in non-hydropic fetuses 2
Delivery Planning
Timing of Delivery
For pregnancies WITHOUT intrauterine transfusions:
- Deliver between 37+0 to 38+6 weeks' gestation 1. This early-term delivery balances the risk of late-gestation fetal anemia (when MCA-PSV becomes less reliable) against complications of prematurity.
For pregnancies WITH intrauterine transfusions:
- Continue IUTs until 35 weeks, then deliver between 37+0 to 38+6 weeks 1. Delaying delivery beyond 37 weeks reduces neonatal exchange transfusion rates from 38% at 34 weeks to 17% after 37 weeks, while minimizing risks of sepsis, electrolyte abnormalities, and necrotizing enterocolitis associated with exchange transfusions 1.
Neonatal Management
Immediate Postnatal Care
- Obtain cord blood for direct antiglobulin test (DAT) and hemoglobin/bilirubin levels
- Monitor for jaundice requiring phototherapy or exchange transfusion
- Maternal antibodies persist up to 6 months postnatally, requiring ongoing monitoring for kernicterus 2
- Approximately 20% of neonates requiring exchange transfusion experience complications (infection, electrolyte imbalance, thromboembolism, cardiac arrhythmia, NEC) 2
Important Clinical Caveats
Anti-Fy^a has documented potential for severe HDFN: While historically considered "usually mild," case series demonstrate that anti-Fy^a can cause severe fetal anemia requiring intrauterine transfusions 3, 4. The 2025 JAMA guidelines explicitly include anti-Duffy among antibodies capable of causing HDFN 1, 2.
Do not underestimate based on low initial titers: Significant hemolysis can occur even with moderate titers, particularly if antibody levels rise during pregnancy 4.
Functional antibody testing may guide management: When the father is heterozygous and titers are high or rising, functional assays demonstrating antibody activity support more intensive surveillance 4.
Avoid routine anti-D prophylaxis confusion: Anti-Fy^a management does not involve immunoglobulin prophylaxis (unlike RhD); management focuses on surveillance and intervention for established alloimmunization 2.